Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

Share Price is delayed by 15 minutes
Get Live Data
12.60    -0.05 (-0.40%)
Bid:
12.60
Ask:
12.95
Spread: 0.35 (2.778%)
Market Cap: £42.85m
BVC Live PriceLast checked at - London Stock Exchange

Intraday Batm Advanced Share Chart

HCV Testing Certification

2 May 2012 07:00

RNS Number : 5067C
BATM Advanced Communications Ld
02 May 2012
 



2 May 2012

 

BATM Advanced Communications Limited

CE certification for HCV (Hepatitis C) screening kit

 

BATM Advanced Communications Limited ("the Company") (LSE: BVC), a leading designer and producer of broadband data and telecoms systems and medical laboratory equipment, is pleased to announce that its wholly owned subsidiary Adaltis, a manufacturer of medical diagnostics equipment, has received CE certification for its HCV (Hepatitis C) Screening Kit.

 

The kit is a fourth generation Enzyme Immunoassay (Elisa) kit for the determination of antibodies to Hepatitis's C virus in human plasma or serum. Testing in external, independent labs has shown performance results of 100% for diagnostic sensitivity and 99.5% for diagnostic specificity, clearly marking this screening kit as the top of its class. This level of accuracy will ensure that patients receive reliable diagnoses and that laboratories are spared the significant and needless expense of repeat testing.

 

The kit enables two different method protocols, one especially developed for the Chinese market and a shorter version for the rest of the world.

 

This certification follows the Company's announcement of 23 March 2012 that it had received CE certification for its Detect 4 HIV Total Screening Kit.

 

Initial deliveries of the new kit will start in the second quarter of this year, with an increasing buildup of production through the fourth quarter and into next year.

 

Dr Zvi Marom, Chief Executive, of BATM commented:

"We're delighted to have received certification for the HCV screening kit which comes just after the clearance for our HIV kit. This is further evidence of the momentum that we are building within our medical division as we continue to add to our portfolio of products."

 

 

- Ends -

 

For further information:

 

Enquiries

 

BATM Advanced Communications +972 9866 2527   

Ofer Bar-Ner, CFO

 

Newgate Threadneedle 020 7653 9850

Josh Royston / Graham Herring

 

finnCap 020 7220 0500

Marc Young / Brian Patient

 

Shore Capital 020 7408 4090 

Pascal Keane

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSSAFLFFESEEI
Date   Source Headline
14th Apr 20229:30 amRNSAnnual Financial Report
13th Apr 20227:00 amRNSAppointment of Non-Executive Director
4th Apr 20227:00 amRNSTransaction in Own Shares and TVR
18th Mar 20227:00 amRNSStrategic Partnership for Edgility with NEXCOM
17th Mar 202210:30 amRNSResult of General Meeting
10th Mar 202212:30 pmRNSHolding(s) in Company
8th Mar 202211:30 amRNSHolding(s) in Company
28th Feb 20227:00 amRNSFull Year Results
23rd Feb 20227:00 amRNSNotice of General Meeting
21st Feb 20227:00 amRNSStrategic Partnership for Edgility with Advantech
17th Feb 20227:00 amRNSTrading Update and Notice of Results
3rd Feb 202211:23 amRNSClarification on FTSE Nationality Review
3rd Feb 20227:00 amRNSUpdate on FTSE Nationality Review & Share Buyback
31st Jan 20227:00 amRNSUpdate on Ador Diagnostics
17th Jan 20227:00 amRNSUpdate on FTSE Nationality Review
4th Jan 20227:00 amRNSDividend Declaration
4th Jan 20227:00 amRNSTotal Voting Rights
16th Dec 20217:00 amRNSFirst sales of rapid COVID-19 test in Russia
14th Dec 202111:45 amRNSResult of AGM and Dividend Declaration
30th Nov 20217:00 amRNSCOVID-19 tests effective in diagnosing Omicron
25th Nov 20213:00 pmRNSBlock Listing Interim Review
22nd Nov 20213:00 pmRNSNotice of AGM and Dividend Declaration
10th Nov 20217:00 amRNSBATM receives $3.5m cyber security contract
3rd Nov 20217:00 amRNSNew five-year contract for Edgility
1st Nov 20217:00 amRNSBATM receives agri-waste contract in Botswana
7th Oct 20217:00 amRNSStrategic partnership for NFV with AudioCodes
13th Sep 20217:00 amRNSFirst enterprise customer for NFV with $2m order
23rd Aug 20217:00 amRNSInterim Results
12th Aug 20217:00 amRNSNotice of Results
12th Jul 20217:00 amRNSLaunch of Edgility networking NFV-based ecosystem
5th Jul 20217:00 amRNSBATM receives $10m cyber security contract
15th Jun 20217:00 amRNSBATM receives $4.1m cyber security contract
26th May 20217:00 amRNSBlock listing Interim Review
18th May 20217:00 amRNSBATM commences delivery of new COVID-19 tests
19th Apr 202110:25 amRNSAnnual Financial Report
12th Apr 20217:00 amRNSStrategic partnership for NFV
29th Mar 20217:00 amRNSBATM develops molecular diagnostics test for TB
19th Mar 20217:00 amRNSCompletion of Sale of NGSoft
11th Mar 20217:00 amRNSBATM launches no-swab saliva-based COVID-19 test
1st Mar 20217:00 amRNSUpdate on Sale of NGSoft
22nd Feb 20217:00 amRNSFull Year Results
11th Feb 20215:38 pmRNSFTSE Nationality Review
1st Feb 20217:00 amRNSTrading Update and Notice of Results
19th Jan 20217:00 amRNSBATM's NFVTime now available for the public cloud
12th Jan 20217:00 amRNSBATM enters option agreement to sell NGSoft
24th Dec 20207:00 amRNSCOVID-19 test effective in diagnosing new strain
17th Dec 20203:50 pmRNSResult of AGM
15th Dec 20207:00 amRNSUpdate on Ador Diagnostics
7th Dec 20207:00 amRNSDelivery of First Insect Protein Recovery Facility
30th Nov 20203:03 pmRNSTotal Voting Rights and Share Capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.